US 11,840,734 B2
Method for analyzing aurka expression
Siegfried Hauch, Hilden (DE); and Markus Sprenger-Haussels, Hilden (DE)
Assigned to Qiagen GmbH, Hilden (DE)
Appl. No. 16/494,949
Filed by Qiagen GmbH, Hilden (DE)
PCT Filed Mar. 1, 2018, PCT No. PCT/EP2018/055016
§ 371(c)(1), (2) Date Sep. 17, 2019,
PCT Pub. No. WO2018/184768, PCT Pub. Date Oct. 11, 2018.
Claims priority of application No. 17164667 (EP), filed on Apr. 3, 2017; and application No. 17164820 (EP), filed on Apr. 4, 2017.
Prior Publication US 2020/0010906 A1, Jan. 9, 2020
Int. Cl. C12Q 1/6886 (2018.01)
CPC C12Q 1/6886 (2013.01) [C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01)] 9 Claims
 
1. A method for determining the effectiveness of an anti-RANKL antibody therapy being administered to a subject afflicted with cancer, the method comprising steps:
(A) isolating RNA from circulating tumor cells obtained from the subject, determining expression of at least AURKA in the RNA isolated from the circulating tumor cells, and generating an expression profile for the circulating tumor cells that includes the determined expression of AURKA in the RNA isolated from the circulating tumor cells;
(B) isolating RNA from extracellular vesicles obtained from the subject, determining expression of at least AURKA in the RNA isolated from the extracellular vesicles, and generating an expression profile for the extracellular vesicles that includes the determined expression of AURKA in the RNA isolated from the extracellular vesicles;
(C) generating a combined expression profile that comprises the determined expression of AURKA for the circulating tumor cells from step (A) and the determined expression of AURKA for the extracellular vesicles from step (B);
(D) identifying whether AURKA is overexpressed in the combined expression profile generated in step (C), wherein overexpressed means that AURKA is expressed in the combined expression profile of the subject above a threshold value predetermined on the basis of normalized AURKA expression data from a plurality of subjects not afflicted with cancer; and
(E) when AURKA is identified in the combined expression profile as being overexpressed in step (D), ceasing the administration of the anti-RANKL antibody therapy previously being administered to the subject and instead administering a therapeutic agent that is different than the anti-RANKL antibody therapy previously administered to the subject to treat the cancer.